Atrial fibrillation (AF) is the most common cardiac arrhythmia in the elderly, affecting 1 in 20 adults over the age of 70 years. Stroke is a major yet highly preventable complication of AF, and the strokes related to AF often are disabling and fatal. Warfarin is the treatment of choice in high-risk patients with AF, and its superior efficacy over aspirin for preventing stroke in these patients is widely recognized. However, several eligible patients with AF are not being treated with warfarin or are being treated inadequately, largely because of concerns regarding the attendant strict monitoring, drug interactions, and risk of major bleeding. As such, alternative antithrombotic therapies that can rival or exceed the efficacy of warfarin, yet compare favorably with its administration and side effect profile, are being sought. One such strategy, the use of a combination antiplatelet regimen, for stroke prevention in high-risk patients with nonvalvular AF was investigated recently in two clinical trials. This article reviews the role of combination antiplatelet regimens in stroke prevention for patients with AF. Other therapies discussed include oral anticoagulation, single antiplatelet therapies, oral anticoagulation plus antiplatelet treatment, direct thrombin inhibitors, and factor Xa inhibitors.
Introduction
Atrial fibrillation (AF) is characterized by disordered electrical activity in the atria that causes an irregular and often rapid contraction of the ventricles [1]. AF may limit itself, recur (paroxysmal), or be persistent (lasting more than 7 days), and its overall prevalence increases with age, from 0.7% in persons aged 55 to 59 years to 18% in those 85 years and older [2] . The major complication of AF is systemic embolism (accounting for ∼50% of all cardiogenic emboli), mostly to the cerebral vascular bed, the latter of which manifests as strokes. After adjustment for other vascular risk factors, AF alone is associated with a three-to fourfold increased risk of stroke, and more than 75,000 cases of AF-related stroke are believed to occur each year in the United States [2] . These strokes generally are larger, more disabling, and more likely to be fatal than strokes of other causes.
Antithrombotic therapy is the cornerstone of stroke prevention among AF patients, and the incidence of ischemic stroke among patients with AF not treated with antithrombotic agents averages 4% to 5% per year, and may be greater than 13% per year in highrisk patients [3] . Oral anticoagulation, which generally involves the use of warfarin, currently is the treatment of choice for mitigating stroke risk in AF patients, but its use is limited by a narrow therapeutic index that demands strict monitoring, several drug and dietary interactions, a lack of firm caregiver commitment to ensure compliance with treatment and follow-up visits, and the risk of major bleeding, including hemorrhagic stroke [1] . Practitioners also have concerns about physical immobility from age-related health problems leading to falls and hemorrhagic complications, and whether participants in clinical trials, who generally are followed up more closely to ensure adherence to the study protocol, are representative of patients seen in "real-world" practice, who may not necessarily be compliant with management protocols.
All the aforementioned factors have led to suboptimal warfarin use in clinical practice, with as many as 50% of eligible AF patients not receiving it, or up to three quarters not being treated adequately. As a result, various alternative antithrombotic therapies have, and continue to be, actively investigated for stroke prevention in patients with AF. One such regimen is combination antiplatelet therapy. This review article discusses up-to-date evidence-based antithrombotic treatment for stroke prevention in AF patients, with a major emphasis on the role of combination antiplatelet therapy.
Antithrombotic treatment
& Stroke in patients with AF is caused mainly by cardiogenic embolism.
Over the years, various clinical trials of antiplatelet and anticoagulant medications to prevent stroke in AF have been conducted with the goal of interrupting the presumed cardioembolic mechanism of stroke in AF. In this section, the results of investigations of pertinent antithrombotic regimens are discussed. [4] . The confidence intervals for the pooled result indicate that the risk reduction across trials was barely significant. Other meta-analyses of aspirin versus control in AF patients have been conducted at the study level, not the patient level, and suggest a 22% (95% CI, 2%-38%) reduction in the risk of stroke in favor of aspirin [5] .
Single antiplatelet therapy (aspirin)
&
Oral anticoagulation
& Pooled results from primary prevention trials of warfarin versus control have shown the superior efficacy of warfarin, which was consistent across studies, with an overall RR reduction of 68% (95% CI, 50%-79%) and an absolute reduction in annual stroke rate from 4.5% in the control patients to 1.4% in patients assigned to adjusted-dose warfarin [6] . Overall, warfarin use has been shown to be relatively safe, with an annual rate of major bleeding of 1.3% on warfarin compared with 1% for patients on placebo or aspirin. The optimal intensity of oral anticoagulation for stroke prevention in patients with AF appears to be 2.0 to 3.0. Data from a large case-control study [7] and clinical trials [8, 9] indicate that the efficacy of oral anticoagulation drops significantly below an international normalized ratio (INR) of 2.0. & Studies comparing oral anticoagulation directly with aspirin suggest the risk reduction associated with oral anticoagulation therapy is much greater than that provided by aspirin. A meta-analysis of these studies reported a 36% (95% CI, 14%-52%) relative reduction in the risk of all stroke with adjusted-dose oral anticoagulation compared with aspirin and a 46% (95% CI, 27%-60%) reduction in the risk of ischemic stroke [5] . A patient-level meta-analysis found an RR reduction of 46% (95% CI, 29%-57%) for all stroke and 52% (95% CI, 37%-63%) for ischemic stroke with anticoagulation versus aspirin therapy [4] . Major hemorrhage was increased 1.7-fold (95% CI for hazard ratio [HR], 1.21-2.41) ( Table 1) .
Oral anticoagulation plus antiplatelet therapy
& Because patients with AF often have coexisting atherosclerotic vascular disease, it is thought that both warfarin and aspirin may be necessary to simultaneously prevent thrombus formation in the left atrium and arteries [1] . Combining low-dose oral anticoagulation with aspirin appears to add relatively little protection against stroke compared with aspirin alone in patients with AF, whereas the combination of aspirin and oral anticoagulation at higher intensities significantly boosted the risk of intracranial hemorrhage, especially in elderly patients [10] . However, in the National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF), patients were stratified into a higher-risk group (AF and rheumatic mitral stenosis or a history of embolism) and a lower-risk group (AF and age 960 years, hypertension, or heart failure) [11] . The higher-risk patients were randomly assigned to treatment with anticoagulation (INR 1.4-2.4) combined with the platelet cyclooxygenase inhibitor triflusal (600 mg/d, approximately equivalent to 300 mg of aspirin) or anticoagulation (INR 2.0-3.0) alone. The lower-risk patients were randomly assigned to receive triflusal alone, anticoagulation (INR 2.0-3.0) alone, or triflusal plus anticoagulation to an INR of 1.25 to 2.0. The group receiving combination therapy had a significantly lower risk of primary outcome events (thromboembolism plus cardiovascular death) than the group treated with anticoagulation alone in both risk groups. Rates of severe bleeding, including intracerebral hemorrhage, were lower in the combination therapy arm than in the anticoagulation-only arm, but this difference was not statistically significant. However, it should be noted that the differences in primary outcome resulted largely from outcomes that probably were not a result of thromboembolism and that the achieved INR levels were similar in the anticoagulation and combination therapy groups. & Currently, there is no evidence that combining anticoagulation with an antiplatelet agent reduces the risk of stroke or myocardial infarction compared with anticoagulant therapy alone in AF patients, but there is clear evidence of increased bleeding risk [10] . Therefore, in general, aspirin should not be added to anticoagulation therapy for AF patients without compelling indications for antiplatelet therapy.
Combination antiplatelet therapy
& Presently there are few data regarding the efficacy of combining antiplatelet agents for stroke prevention in AF patients [12] . Available studies have examined the clinical impact of aspirin plus clopidogrel in AF patients. Clopidogrel is an adenosine diphosphate (ADP) receptor antagonist. Clopidogrel selectively and irreversibly inhibits ADP-induced fibrinogen binding to its receptor on platelets, thereby affecting ADP-dependent activation of the glycoprotein IIb/IIIa complex, the major receptor for fibrinogen present on the platelet surface. Table 2 ). The benefit of the combination in reducing major vascular events, however, was balanced by an increased risk of major hemorrhages (major vascular events decreased 0.8% per year, major hemorrhages increased 0.7% per year; RR, 0.97; 95% CI, 0.89-1.06; P=0.54). Major bleeding among patients assigned to receive clopidogrel plus aspirin versus those on aspirin alone was 2.0% versus 1.3% per year (RR, 1.57; 95% CI, 1.29-1.92). Clopidogrel plus aspirin reduced the risk of stroke by 28% but increased the risk of major extracranial hemorrhage by 51% (affecting predominantly the gastrointestinal tract) and major intracranial hemorrhage by 87% (Table 1) .
Direct thrombin inhibitors
& Ximelagatran, a direct thrombin inhibitor, was compared with doseadjusted warfarin in two major randomized controlled trials. In pooled analyses of both trials [10] , the rate of main events (combined ischemic stroke, hemorrhagic stroke, and systemic embolic event) was similar in the ximelagatran and warfarin groups (1.62% vs 1.65% per year). Conflated rates of minor and major bleeding were lower with ximelagatran (31.7% vs 38.7% per year; PG0.0001), but serum alanine aminotransferase values rose transiently to more than three times the normal level in the subjects on ximelagatran (6.1% vs 0.8%; PG0.0001). Although these increases usually are reversible, they led the US Food and Drug Administration (FDA) to decide against approving ximelagatran for stroke prevention. & Dabigatran etexilate is a prodrug given orally in a fixed dose and quickly converted by cytochrome P-450-independent esterases to dabigatran, a powerful reversible direct competitive inhibitor of thrombin with a prompt onset of action, consistent anticoagulant effect, and half-life of 12 to 17 h. RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy), a prospective, open-label, randomized trial with blinded assessment of all outcomes, investigated whether dabigatran is noninferior to warfarin. [15.
••]. More than 18,000 patients with nonvalvular AF and at least one risk factor for stroke were randomly assigned to receive fixed doses of dabigatran (110 or 150 mg twice daily) or open-label, adjusted-dose warfarin (INR 2.0-3.0). After 2 years, the rates of systemic embolism or stroke 
FDA-approved treatments
Pharmacologic treatment & The current FDA-approved pharmacologic therapies for stroke prevention in patients with AF include dose-adjusted warfarin (targeted to INR 2.0-3.0) and antiplatelet agents, as discussed earlier [18, 19] . The only antiplatelet agents discussed in this section are aspirin and clopidogrel, as these are the two antiplatelets shown to reduce the rate of stroke in patients with AF. 
Antiplatelet agents

